UPB Stock Forecast & Price Target

Upstream Bio is attractive because verekitug has already produced compelling Phase 2 proof of concept in severe asthma and CRSwNP, including a 56% reduction in annualized asthma exacerbations at 100mg every 12 weeks and meaningful improvements in nasal polyp and congestion scores, while maintaining a consistent safety and tolerability profile. Its appeal is strengthened by clear differentiation versus approved biologics through quarterly at-home dosing, a TSLP-receptor mechanism that may offer broader upstream control of inflammation, and validation from teze­pelumab’s success in the same pathway. Financially, the company reported $207.4 million in cash and equivalents expected to fund operations through 2027, with additional upside from the completed 480-patient COPD trial and >90% retention in the VALOUR LTE.

Upstream Bio is viewed negatively because its limited cash runway and the substantial cost of advancing pivotal asthma and CRSwNP programs create a financing overhang, with management’s cash expected to fund operations only through 2027 and a meaningful equity raise likely in 2H27. Although the February 11, 2026 Phase 2 VALIANT data in severe asthma were positive, the stock still fell approximately 70% from $27.81 on February 10, 2026 to $8.33 on February 17, 2026, indicating severe investor skepticism despite a roughly 56% AAER reduction versus placebo. That skepticism is reinforced by inconsistent durability across doses, since 400mg every 24 weeks produced only about a 39% AAER reduction, while the company must still prove that its Phase 3 asthma and CRSwNP plans can be funded and executed without excessive dilution.